戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 for preventing oral premalignant lesions and second primary tumors.
2 CC patients per year will develop additional second primary tumors.
3 l of premalignant lesions, and prevention of second primary tumors.
4 ase reduce the risk of tobacco smoke-related second primary tumors.
5 ascular disease, diabetes, osteoporosis, and second primary tumors.
6 patients who are at high risk for developing second primary tumors after surgical removal of the init
7  since chemotherapy in these 68 survivors, 7 second primary tumors and 8 opportunistic infections wer
8 d for up to 90 months for the development of second primary tumors and local recurrences.
9 tance in assessing individuals for risk of a second primary tumor as well as in devising effective st
10 was analyzed in a competing risk model, with second primary tumors as competing risk.
11 tologic criteria, these relapses represented second primary tumors developing in the conservatively t
12         To date, one patient has developed a second primary tumor in the aerodigestive tract.
13           A total of 3 patients (1.9%) had a second primary tumor in the contralateral tonsil, includ
14 ignant lesions), and tertiary (prevention of second primary tumors in previously treated patients), a
15 iously irradiated, locoregional recurrent or second primary tumors in the head and neck, and describe
16  premalignant lesions and the development of second primary tumors in those already treated for squam
17 or pack-years and other factors, and risk of second primary tumors increased by 1.5% per pack-year (H
18 the apical urethral margin and the risk of a second primary tumor of the retained urethra, all of whi
19 tween the two groups in the time to failure [second primary tumors plus local recurrences: relative r
20         The synchronous contralateral tonsil second primary tumor rate in the bilateral surgery group
21        The metachronous contralateral tonsil second primary tumor rate in the unilateral surgery grou
22 dly low metachronous contralateral tonsillar second primary tumor rates and no compromise in survival
23 ronous and metachronous contralateral tonsil second primary tumor rates.
24 arcinoma of the head and neck (SCCHN) or new second primary tumor (SPT) in a previous radiation field
25                           The development of second primary tumors (SPTs) in patients with head and n
26 ontrolled trial to evaluate the incidence of second primary tumors (SPTs) in patients with resected n
27 d have a lifelong risk to develop non-ocular second primary tumors (SPTs) involving multiple other or
28 N-alpha) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carci
29 e II adjuvant trial to prevent recurrence or second primary tumors (SPTs) using 13-cRA, IFN-alpha, an
30                           The 3-year rate of second primary tumors was 7% with MPR-R, 7% with MPR, an
31 arcinoma are at high risk for development of second primary tumors, which pose the main threat to sur